Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $66.69 USD
Change Today -0.79 / -1.17%
Volume 556.1K
Q On Other Exchanges
Symbol
Exchange
Berlin
As of 8:04 PM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

quintiles transnational hold (Q) Key Developments

Quest Diagnostics Inc., Quintiles Transnational Holdings Inc. - Special Call

To discuss definitive agreement between Quintiles and Quest Diagnostics to form a global clinical trials laboratory services business

Quintiles and Quest Diagnostics to Form Joint Venture to Provide Global Clinical Trials Laboratory Services

Quintiles and Quest Diagnostics announced a definitive agreement to form a global clinical trials laboratory services business. By combining the clinical trials laboratory operations of two industry leaders, the new entity will provide customers with the depth of capabilities and end-to-end clinical trial laboratory services required to succeed in the increasingly complex biopharmaceutical industry. The new entity will offer a compelling value proposition to solidify its position as the second-largest central laboratory services company in the world. The joint venture would have generated approximately $575 million in revenues in 2014, and will offer a superior breadth of services and test menu to its customers across all segments of the biopharmaceutical industry – a group that includes all of the top-20 large biopharmaceutical companies. Upon closing of the transaction, Quintiles will own 60% and Quest Diagnostics will own 40% of the new joint venture. Quintiles’ scale, clinical trial expertise, and diverse therapeutic experience coupled with Quest Diagnostics’ operational, scientific and quality excellence, supply chain network and informatics promise greater innovation, quality and value for biopharmaceutical customers. In addition, customers will benefit from a globally scaled and agile business model that is singularly focused on delivering top-quality laboratory services informed by deep medical and clinical knowledge. Clinical, scientific and statistical excellence is becoming increasingly important for successful laboratory work as part of the regulatory approval process. To meet these needs, the entity will draw upon the deep scientific, medical and data expertise of Quintiles and Quest Diagnostics, which together have a team of approximately 3,500 medical doctors, Ph.D.s and biostatisticians as well as cutting-edge experience, expertise and capabilities in the areas of genomics and precision medicine. The new entity also will leverage a number of additional resources from the broader Quintiles and Quest Diagnostics organizations, including the Infosario® technology platform and Quest Diagnostics’ robust data analytics capabilities. Both companies are bioinformatics leaders in their respective fields – positions that have been built upon and honed from diverse experience and data access. Quest Diagnostics draws from 20 billion test results, and Quintiles’ assets include electronic health records representing more than 60 million patient lives and a network of 250,000 clinical investigators. The joint venture will be led by an experienced global management team appointed from Quintiles and Quest Diagnostics. Built upon the strong histories and foundations of quality delivery of its parent organizations, the new entity will provide customers with a variety of advanced testing capabilities and services. These will enable end-to-end companion diagnostic development with regulatory, reimbursement and commercial strategies, to help biopharmaceutical customers’ precision medicine efforts. It also will help enhance quality and efficiency by leveraging Quest Diagnostics’ supply chain that serves approximately half of the physicians and hospitals in the U.S. and includes 2,200 service centers, 3,000 couriers and connectivity solutions used by 250,000 healthcare providers.

Quintiles Transnational Seeks Acquisitions

Quintiles Transnational Holdings Inc. (NYSE:Q)'s Chief Executive Officer Tom Pike said, "We also are looking for non-US-based acquisitions, clearly a priority over time. In addition, we look at analytical areas, so in the IHS segment, for instance, to supplement the market-access capabilities that we already have or to supplement our real-world [late phase] capabilities, we would look for more analytically oriented acquisitions. So we continue to look around the world."

Quintiles Transnational Holdings Inc. Presents at 3rd Annual Regen Med Investor Day, Mar-25-2015 08:55 AM

Quintiles Transnational Holdings Inc. Presents at 3rd Annual Regen Med Investor Day, Mar-25-2015 08:55 AM. Venue: Metropolitan Club, One East 60th Street, New York, NY 10022, United States. Speakers: John Doyle, SVP & Managing Director, Global Market Access & Commercial.

Quintiles Transnational Holdings Inc. Presents at Barclays Global Healthcare Conference, Mar-10-2015 11:15 AM

Quintiles Transnational Holdings Inc. Presents at Barclays Global Healthcare Conference, Mar-10-2015 11:15 AM. Venue: Loews Miami Beach Hotel, 1601 Collins Avenue, Miami, Florida, United States. Speakers: Thomas H. Pike, Chief Executive Officer and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
Q:US $66.69 USD -0.79

Q Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Charles River Laboratories International Inc $78.26 USD +0.02
ICON PLC $68.98 USD +0.14
IMS Health Holdings Inc $27.19 USD -0.32
INC Research Holdings Inc $30.68 USD -1.01
PAREXEL International Corp $68.65 USD -0.68
View Industry Companies
 

Industry Analysis

Q

Industry Average

Valuation Q Industry Range
Price/Earnings 24.5x
Price/Sales 2.0x
Price/Book NM Not Meaningful
Price/Cash Flow 23.4x
TEV/Sales 1.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact QUINTILES TRANSNATIONAL HOLD, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.